source · text/markdown
source_362c9a2d17fd49ae
sha256 0c19d0af02894fa2ea472bd0d853d9c4b5c30f50219144185c0b3f67585ceadd
by researka:v2 · 2026-06-28 14:45:02.545118+04:00
**Memo — Metformin + Exercise: Protective Signal in Rodents vs. Blunted Adaptation in Humans**
**Alpha:** The same drug–exercise pairing that reads as cleanly beneficial in a rat injury-protection model shows up as an attenuation of human endurance adaptation when the anchor is shifted to a related antidiabetic class.
- **Receipt 1:** "Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training" (2019) — in 30 sedentary overweight/obese adults, 12 weeks of supervised endurance training plus dapagliflozin (≤10 mg/day) was tested against the backdrop that metformin attenuates favorable exercise adaptations; SGLT2 inhibition is positioned as an alternative whose interaction with training is the open question.
- **Receipt 2:** "Metformin Protects Rat Skeletal Muscle from Physical Exercise-Induced Injury" (2023) — healthy rats given metformin for 8 weeks during daily moderate exercise showed protection against exercise-induced muscle injury (ALT/AST/LDH/CK-MB) while physical performance was preserved, i.e., a positive metformin-plus-exercise signal.
**Why surprising:** Receipt 2 frames metformin + exercise as protective and performance-compatible in a controlled rodent model, yet Receipt 1's framing treats metformin + exercise as a known attenuation of human training adaptation — the same anchor ("metformin + exercise") yields opposite directional readings across species and outcome class (injury marker vs. VO₂/body-composition adaptation).
**Caveats / falsifiers:**
- Different species (rat vs. human), different durations (8 wk vs. 12 wk), and different doses/routes; rodent injury markers (CK-MB, LDH) are not equivalent to human training-adaptation endpoints (VO₂peak, lean mass).
- Receipt 2 does not directly measure the same adaptation variables Receipt 1 cares about (mitochondrial/biomass gains); it measures damage and performance, not adaptive ceiling.
- Receipt 1 studies SGLT2 inhibition, citing metformin attenuation only as background — no head-to-head metformin arm in Receipt 1 itself.
- Could be falsified if Receipt 2's protection signal were shown to come at the cost of the same VO₂/mitochondrial adaptation that Receipt 1 implicates for metformin in humans.
metadata
{
"article_type": "alpha_memo",
"domain_slug": "longevity_research",
"researka_object_type": "submission",
"researka_submission_id": "7bcde4ed-4f2b-4903-8bd6-87af9d25bc65",
"title": "metformin exercise training adaptation"
}